Saturday, October 7, 2017: 12:30 PM Background. Candida species are the fourth leading cause of nosocomial bloodstream infections in the United States, however incidence is low and most patients who receive empiric treatment do not actually have candidemia. Unfortunately, detection, identification and susceptibility testing using standard instrumented blood culture systems and routine microbiological techniques takes 4-10 days. Astute clinicians may empirically treat patients with antifungal therapy (AFT) prior to having any results, often leading to unnecessary coverage for candida infection for up to 10 days. The T2 Candida Panel is an FDA-approved assay that rapidly detects the presence of 5 Candida species directly from whole blood in 3-5 hours. We determined whether AFT decisions were altered based on negative (neg) results of a T2 assay.
Rapid Detection of Pediatric Bacteriuria Using Narrow Angle Forward Laser Scattering Technology (NAFLST) with Bacterioscan
Background. Pediatric urinary tract infections (UTI) are common, but culture-based diagnosis can take up to 48 hours. This time delay means patients are exposed to potentially unnecessary antibiotics. The sensitivity of screening urinalysis can vary, so rapid detection of UTI by another means would be beneficial. Narrow Angle Forward Laser Scattering Technology (NAFLST) with Bacterioscan can rapidly detect bacteriuria by shining a laser continuously through a liquid sample containing replicating bacteria, and graphing the degree of light refraction over time. Higher degrees of light refraction represent higher initial bacterial load and continued bacterial growth. After 3 hours, the optical scatter classifies a sample as either Likely Positive or Likely Negative. We compared Bacterioscan results to culture data in pediatric patients to assess the ability to diagnose UTI and avoid unnecessary urine culture.
Methods. This protocol was approved by the UNC Biomedical Institutional Review Board. Over one month, 169 pediatric (<18 yo) urine cultures were collected as part of routine patient care. An individual urine sample and 2.5mL of Sterile Tryptic Soy Broth were pipetted into a Bacterioscan micro-curette. Bacterioscan labeled the specimen as Likely Positive or Likely Negative after a 3 hour period. Results were then compared with urine culture results obtained by routine microbiologic methods.
Results. Of the 169 urine cultures, 96 were positive, but only 27 were positive for uropathogens. Bacterioscan was 100% sensitive and 58.4% specific in predicting clinically relevant/pathogenic bacterial growth in culture (PPV 31.3%, NPV 100%), and 70.8% sensitive and 75.3% specific in predicting any bacterial growth (PPV 79.0%, NPV 66.2%). If a "Likely Positive" Bacterioscan result had been used in our study population to screen urine samples for culture, then 58% (83/142) of negative urine cultures would have been eliminated with no UTIs missed.
Conclusion. By rapidly identifying urine cultures likely to be positive, NAFLST with Bacterioscan can safely obviate the plating of every urine sample and reduce empiric antibiotic use while waiting for culture results. Larger studies are required to confirm these results.
Disclosures. A. Cline, Bacterioscan: Equipment necessary to perform this study was provided by Manufacturer, Equipment necessary to perform this study; R. Jhaveri, Gilead: Investigator, Research support; Abbvie: Investigator, Research support; Merck: Grant Investigator, Research grant October 7, 2017: 12:30 PM Background. Blood cultures can have low sensitivity if a patient is pretreated with antibiotics. A molecular diagnostic for bloodstream infection (BSI) that can also quantitate pathogen DNA could be a useful tool in detecting and monitoring culture-negative infections.
Direct Detection and Quantification of Bacterial Cell-free DNA in Patients with Bloodstream Infection (BSI) Using the Karius Plasma Next Generation Sequencing (NGS) Test
Methods. We prospectively enrolled 75 patients (50 with culture confirmed BSI due to Staphylococcus aureus [n = 21] or Gram-negative bacilli [n = 29] at baseline, and 25 with negative blood cultures) to evaluate the Karius plasma next generation sequencing (NGS) test to detect BSI. Blood samples from patients with confirmed BSI were collected for the study within one day of positive blood culture and then every 2-3 days. Cell-free DNA (cfDNA) was extracted from plasma and underwent NGS in the Karius CLIA/CAP laboratory (Redwood City, CA). After removal of human sequences, remaining reads were aligned against a curated pathogen database. Organisms present at a significance-level above a predefined threshold were reported. Quantity of cfDNA for each reported pathogen was expressed as molecules per microliter (MPM).
Results. When compared with baseline blood culture, the plasma NGS test had a positive agreement of 80% (40/50) and negative agreement of 84% (21/25). Overall, serially collected samples were positive by plasma NGS testing significantly longer than blood culture (mean 6.0 days vs. 2.4 days, respectively; P < 0.0001. Figure) . Patients with BSI were positive longer by NGS testing than blood culture for both S. aureus (mean 6.9 days vs. 4.0 days, respectively; P < 0.005) and gram-negative bacilli (mean 5.4 days vs. 1.3 days, respectively; P < 0.001). Pathogen cfDNA in BSI patients, quantified as MPM, declined over time during treatment. S. aureus MPM declined more slowly than gram-negative MPM and was significantly higher than gram-negative MPM at day 6 (P < 0.001).
Conclusion. The Karius plasma NGS test can directly detect pathogens in patients with BSI. Pathogen cfDNA signal in plasma remains positive longer than blood culture and combined with quantification of pathogen cfDNA, could be a useful biomarker to aid in diagnosis and monitoring of infections, particularly in those with sterile blood cultures.
